

17<sup>th</sup> June 2020

To  
Bombay Stock Exchange Limited  
Dept. of Corporate Services  
Floor 25, Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai :: 400 001  
BSE Scrip Code : 533014

To  
National Stock Exchange of India Ltd  
Listing Dept.  
Exchange Plaza, Bandra Kurla Complex  
Bandra [E]  
Mumbai :: 400 051  
NSE Scrip Code :SICAGEN

Dear Sirs,

**Sub: Outcome of the Board Meeting**

This is to inform that the Board of Directors of the Company at their meeting held today, has inter alia considered and approved the audited financial results (both standalone & consolidated results) of the Company for the quarter and year ended 31<sup>st</sup> March 2020.

The Board has also considered and recommended equity dividend @ 5% (50 paise per share) for the financial year 2019-20, subject to the approval of shareholders in the ensuing Annual General Meeting.

Pursuant to Regulation 33 of the SEBI (LODR) Regulation 2015, copies of the aforesaid financial results are herewith attached.


The above information may kindly be taken on record.

Thanking you,

Yours faithfully,  
For Sicagen India Limited



R.Chandrasekar  
Whole Time Director  
Encls : a/a



**Sicagen India Ltd.**

Registered & Corporate Office :

4th Floor, Spic House, 88, Mount Road, Guindy, Chennai-600 032, INDIA

Tel : +91 44 4075 4075 | Fax : +91 44 4075 4999 | info@sicagen.com

CIN : L74900TN2004PLC053467 | www.sicagen.com